VOQP Stock Overview
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
VioQuest Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| VOQP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.1% | 0.7% |
| 1Y | n/a | 9.5% | 23.9% |
Return vs Industry: Insufficient data to determine how VOQP performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VOQP performed against the US Market.
Price Volatility
| VOQP volatility | |
|---|---|
| VOQP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: VOQP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VOQP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | n/a |
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company’s products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors.
VioQuest Pharmaceuticals, Inc. Fundamentals Summary
| VOQP fundamental statistics | |
|---|---|
| Market cap | US$6.00 |
| Earnings (TTM) | -US$11.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs VOQP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VOQP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.15m |
| Earnings | -US$11.15m |
Last Reported Earnings
Jun 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VOQP perform over the long term?
See historical performance and comparison